MSD’s ADC gains OS win but PFS miss in Phase III stomach cancer trial
MSD’s TROP2-targeting antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT), has offered a significant overall survival (OS) benefit in another Phase III…
MSD’s TROP2-targeting antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT), has offered a significant overall survival (OS) benefit in another Phase III…